Published on October 22, 2013 at 11:00 AM
Novozymes Biopharma is teaming up with Almac to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements. The collaboration will allow clients to use Almac's manufacturing assets and protein conjugation capability to link Novozymes' Recombumin® Flex technology to their peptide and small molecule drugs, which the firms say improves pharmacokinetics and has been shown to improve drug targeting in oncology and rheumatoid arthritis. Collaborations with commercial partners have reportedly already begun, and the companies hope collaborations will continue to expand in early 2014.
Novozymes says that its Recombumin Flex technology will be this collaboration's focal point. Novozymes modified the amino acid sequence of human albumin to increase its receptor affinity, which the firm says not only can improve half-life extension and drug targeting, but complements Almac's peptide and small molecule manufacturing expertise and could also be allied to its protein conjugation technology offerings.
"This alliance has clear benefits for companies involved in both drug development and delivery technologies: a complete service can be recommended utilizing the core expertise of both parties at an early stage of clinical development, thus significantly enhancing the success of drug development programs," Denis Geffroy, vp, business development for Almac, said in a statement.
This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.